孟鲁司特钠对慢性阻塞性肺疾病患者肺功能及血液流变学的影响

目的探讨孟鲁司特钠对慢性阻塞性肺疾病（COPD）患者肺功能及血液流变学的影响。方法选择本院2008年1月-2008年10月60例临床拟诊COPD的患者按照就诊顺序随机分为孟鲁司特钠组和对照组，每组30例，并设30例体检健康者作为对照组，对照组给予常规治疗，孟鲁司特钠组在对照组基础上联合孟鲁司特钠10mg，每晚1次，治疗4周，治疗前后分别检测肺功能及血液流变学。结果COPD的患者血液流变学较健康组均明显升高（P〈0．01）；第1S用力呼吸容积（FEV1）占预计值的百分比（FEV1％）和FEV1与用力肺活量（FVC）的比值（FEV1／FVC（％））较健康组均明显降低，具有统计学意义（P〈0．01）；与治疗前比较，孟鲁司特钠组治疗后FEV1％及FEV1／FVC（％）水平明显升高（P〈0．01），血液流变学指标明显降低（P〈0．01）；与对照组治疗后比较，孟鲁司特钠组高切全血黏度、低切全血黏度、血浆黏度均明显下降，FEV1％及FEV1／FVC（％）明显上升，差异均具有统计学意义。结论孟鲁司特钠对COPD患者有较好的临床治疗及预防作用。

Effect of montelukast on hemorheology and lung function in patients with chronic obstructive pulmonary diseases

Objective To determine the therapeutic effect of hemorheology and lung function with montelukast on patients with chronic obstructive pulmonary diseases （COPD）. Methods Sixty patients with COPD from January 2008 to October 2008 were randomly divided into 2 groups： a montelukast group and a control group, 30 patients in each group, and 30 healthy persons as healthy control group. The control group received routine treatment. The montelukast （10 mg per night for 4 weeks） group received montelukast and the rountine treatment. The clinical conditions were checked before and after the treatment, including lung function and hemorheology. Results Hemorheology in the montelukast group was significantly decreased than that in the control group after the treatment. The levels of FEV1 % and FEV1/FVC （%） were significantly increased in the montelukast group as compared with the control group after the treatment. The difference had statistical significance. Conclusion Montelukast has treatment and prophylactic effect on patients with COPD.